Table 1 Demographic and clinical characteristics of the study population
Characteristics | Total (n = 186) | Adverse Event Group (n = 33) | No Adverse Event Group (n = 153) | P-value |
|---|---|---|---|---|
Age, years | 30.88 ± 4.70 | 31.21 ± 3.45 | 30.81 ± 4.48 | .635 |
Body mass index, kg/m2 | 24.50 ± 3.19 | 24.97 ± 2.98 | 24.40 ± 3.23 | .354 |
Gestational age at start of therapy, weeks | 29.60 ± 3.91 | 28.97 ± 4.23 | 29.74 ± 3.85 | .308 |
Maximum infusion rate, mg/min | 0.083 ± 0.030 | 0.096 ± 0.044 | 0.080 ± 0.026 | .006 |
Comorbid conditions, N (%) | ||||
Twin or multiple gestation | 16 (8.6) | 4 (12.1) | 12 (7.2) | .491 |
Diabetes mellitus | 13 (7.0) | 3 (9.1) | 10 (6.5) | .729 |
Uterine infection | 15 (8.1) | 1 (3.0) | 14 (9.2) | .475 |